Innovus Pharma Launches FlutiCare™ OTC Nasal Spray Allergy Relief in the U.S.
Product Currently Expected to Generate $10-15M in Additional Revenues Annually
Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage
pharmaceutical company that delivers safe, innovative and effective over-the-counter (“OTC”) medicine and consumer care products to improve men’s and women's health and respiratory diseases, today
announced that it has officially launched FlutiCare™ OTC in the U.S. FlutiCare™ contains the most prescribed nasal steroid active
pharmaceutical ingredient (“API”) and form for nasal allergy relief over the last 7 years. The Company is launching FlutiCare™ in
over 10,000 independent pharmacies, direct and through Amerisource Bergen and McKesson, via its Beyond Human® extensive print media
platform and through its extensive online channels and distributors, including its own website, Amazon, and Walmart online stores.
As a second phase of its launch, Innovus Pharma will launch FlutiCare™ to large retail stores.
FlutiCare™ will be available OTC with the same prescription strength and same delivery method as Flonase®* and ClariSpray®*. The
Company currently believes that FlutiCare™ will be the most affordable fluticasone propionate nasal spray on the market and is now
available in one dose, a 30 Day (120 Sprays) treatment and is the only one providing an monthly autoship plan.
“We are very excited to launch FlutiCare™ OTC and provide all patients with allergy relief,” stated Dr. Bassam Damaj, President
and Chief Executive Officer of Innovus Pharma. “FlutiCare™ traces its roots as the most prescribed Rx 24-hour nasal allergy spray
API and form in the U.S. over the past 7 years by a factor of over 10 to 1,” he continued.
FlutiCare™ was approved by the U.S. Food and Drug Administration (“FDA”) for OTC availability through Innovus Pharma’s partner’s
approved abbreviated new drug application (“ANDA”) No. 207957. FlutiCare™ allergy relief joins the growing Innovus Pharma product
family, offering a burgeoning portfolio of non-prescription medicine and consumer care supplements to consumers.
FlutiCare™ becomes the Company’s second available allergy relief product along with AllerVarx™, a patented dietary supplement
formulated to provide relief during the allergy season, already on the market.
In addition, the Company, pending FDA’s guidance, plans to move forward with a fluticasone kit for nasal allergy containing
FlutiCare™ and our upcoming saline nasal spray NasaVa™.
About FlutiCare™
FlutiCare™ is a nasal spray, which provides 50 micrograms of fluticasone propionate (“USP”) per spray, a nasal corticosteroid
that provides 24-hour temporary relief of seasonal and perennial nasal allergy symptoms. FlutiCare™ can be used to relieve both
indoor and outdoor nasal allergy symptoms caused by pollen, dust, animal dander, and other indoor and outdoor allergens. Nasal
allergy symptoms include, nasal congestion, runny nose, sneezing, itchy nose, etc.
FlutiCare™ contains the nasal steroid API that is physician recommended and consumer preferred
- #1 form used by patients;
- #1 nasal steroid active prescribed by physicians;
- Familiar to patients, comfort of a known & trusted medicine;
- Engrained in patients’ allergy management; and
- Effective and safe.
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer goods and specialty pharmaceutical company engaged in the
commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve
men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and
packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial
partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our
on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and
branded Abbreviated New Drug Application (“ANDA”) products, men’s and women’s health supplements, related diagnostics and medical
devices. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change
from prescription (or Rx) to OTC, as well as related products.
For more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.urivarx.com ; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com ; www.recalmax.com; www.prostagorx.com; www.fluticare.com; www.allervarx.com; and www.apeaz.com .
Innovus Pharma's Forward-Looking Safe Harbor:
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information
contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties
that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the
Company, including, but not limited to, projected revenues from the FlutiCare™ product in the United States if approved in that
country, estimated market for its products, and statements about achieving its other development, growth, commercialization,
financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual
results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors
set forth in the Company's most recent filing on Form S-1, annual report on Form 10-K, subsequent quarterly reports filed on Form
10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the
Company.
*Flonase® is a registered trademark of GSK and ClariSpray® is a registered trademark of Bayer.
Emerging Markets Consulting, LLC
James S. Painter III, 407 340 0226
jamespainter@emergingmarketsllc.com
or
myEPK Media
Matt Anthes
424 256 9375
Matt@myEPKMedia.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20171114005563/en/